[go: up one dir, main page]

AR003176A1 - A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER - Google Patents

A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER

Info

Publication number
AR003176A1
AR003176A1 ARP960103861A AR10386196A AR003176A1 AR 003176 A1 AR003176 A1 AR 003176A1 AR P960103861 A ARP960103861 A AR P960103861A AR 10386196 A AR10386196 A AR 10386196A AR 003176 A1 AR003176 A1 AR 003176A1
Authority
AR
Argentina
Prior art keywords
cancer
pharmaceutical composition
inhibit
growth
griseofulvin
Prior art date
Application number
ARP960103861A
Other languages
Spanish (es)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR003176A1 publication Critical patent/AR003176A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

Se describe una composición farmacéutica para el tratamiento de cáncer o tumores en mamíferos que contiene griseofulvina. Puede usarse un agentequimioterapéutico junto con griseofulvina como potenciador. La griseofulvina puede también usarsepa ra tratar infecciones virósicas, sola, junto con otrosagentes virósicos o con un potenciador.A pharmaceutical composition for the treatment of cancer or tumors in mammals containing griseofulvin is described. A chemotherapeutic agent can be used in conjunction with griseofulvin as an enhancer. Griseofulvin can also be used to treat viral infections, alone, together with other viral agents, or with an enhancer.

ARP960103861A 1995-08-03 1996-08-02 A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER AR003176A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US183995P 1995-08-03 1995-08-03
US67418196A 1996-07-16 1996-07-16

Publications (1)

Publication Number Publication Date
AR003176A1 true AR003176A1 (en) 1998-07-08

Family

ID=26669547

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103861A AR003176A1 (en) 1995-08-03 1996-08-02 A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER

Country Status (16)

Country Link
EP (1) EP0841914A2 (en)
JP (1) JPH11511136A (en)
KR (1) KR19990036137A (en)
AR (1) AR003176A1 (en)
AU (1) AU713031B2 (en)
BR (1) BR9609920A (en)
CA (1) CA2228503A1 (en)
CZ (1) CZ30598A3 (en)
HU (1) HUP9903506A3 (en)
IL (1) IL123094A0 (en)
MX (1) MX9800945A (en)
NO (1) NO980420L (en)
PL (1) PL324905A1 (en)
SK (1) SK14298A3 (en)
TR (1) TR199800244T2 (en)
WO (1) WO1997005870A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
EP2055313B1 (en) * 1998-11-09 2015-04-29 Biogen Idec Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
ATE489080T1 (en) * 2001-06-25 2010-12-15 Ajinomoto Kk ANTITUMORAL AGENTS
EP2008652A1 (en) * 2007-06-28 2008-12-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
EP2204367A1 (en) 2008-12-22 2010-07-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
KR102856472B1 (en) * 2021-10-21 2025-09-11 숙명여자대학교산학협력단 Combination therapy with griseofulvin for blood cancer

Also Published As

Publication number Publication date
SK14298A3 (en) 1998-09-09
CZ30598A3 (en) 1998-06-17
HUP9903506A2 (en) 2000-06-28
EP0841914A2 (en) 1998-05-20
BR9609920A (en) 1999-07-06
JPH11511136A (en) 1999-09-28
MX9800945A (en) 1998-04-30
AU6683496A (en) 1997-03-05
KR19990036137A (en) 1999-05-25
WO1997005870A3 (en) 1997-04-17
NO980420D0 (en) 1998-01-30
WO1997005870A2 (en) 1997-02-20
IL123094A0 (en) 1998-09-24
PL324905A1 (en) 1998-06-22
CA2228503A1 (en) 1997-02-20
TR199800244T2 (en) 1998-09-21
NO980420L (en) 1998-04-03
AU713031B2 (en) 1999-11-18
HUP9903506A3 (en) 2000-07-28

Similar Documents

Publication Publication Date Title
AR003176A1 (en) A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER
ES2038659T3 (en) PHARMACEUTICAL ANTIMICROBIAL COMPOSITION TOPIC WHICH INCLUDES A SILVER COMPOUND AND A AZOL.
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
MY121548A (en) Compounds and methods for the treatment of cancer
BG98902A (en) IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKIN INHIBITORS
DK0650483T3 (en) (3R, 4R) -Delta6-tetrahydrocannabinol-7-acids
FI963232A0 (en) Acidified nitrite as an antimicrobial agent
BR9812122A (en) Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
MX9505182A (en) Therapeutical composition for topical application, containing a p substance antagonist.
AU3887797A (en) Pentafluorobenzenesulfonamides and analogs
MX9400434A (en) TEMOZOLOMIDE ENHANCEMENT IN HUMAN TUMOR CELLS.
MX9308013A (en) 4-FENIL-PIRIDONAS AND 4-FENIL-2-FENIL-2-ALCOXIPIRIDINAS SUBSTITUTED, PROCEDURE FOR ITS PREPARATION AND MEDICINES THAT CONTAIN THEM.
CO5050328A1 (en) SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS
CA2245890A1 (en) Use of an extract of cimicifuga racemosa
BR9712141A (en) Application of 1-hyphroxy-2-pyridones to treat skin infections.
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
MD960168A (en) Method for treatment of viral infections and compounds therefor
TR200101693T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
UY26648A1 (en) VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION
BR9908838A (en) Use of a glucocorticoid, process to treat acute or chronic glomerulonephritis, and pharmaceutical composition to treat glomerulonephritis
UY26498A1 (en) SUBSTITUTED PYRROLES
ES2031462T3 (en) PROCEDURE TO PRODUCE 1-B-D-ARABINOFURANOSILCITOSINA-5'-STERARILFOSFATO MONOSODICO AND MONOHIDRATO OF THE SAME, AND PHARMACEUTICAL COMPOUND THAT CONTAINS THIS LAST.
ATE353639T1 (en) IN VITRO USE OF ASTAXANTHIN FOR PRETREATING CELLS PRIOR TO UV RADIATION TO INHIBIT NF-KB ACTIVATION
ES2128353T3 (en) TOPIC COMPOSITION CONTAINING PENCICLOVIR.
DE69625910D1 (en) PENAMSULPHONES AS BETA LACTAMASE INHIBITORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal